Navigation Links
Cellceutix Cancer Drug Kevetrin™ Shows No Genotoxicity in Study
Date:3/2/2011

BEVERLY, Mass., March 2, 2011 /PRNewswire/ -- Cellceutix Corporation (Pink Sheets: CTIX) today announced that it has received more data on Kevetrin™, the Company's flagship compound for the treatment of cancers. Analysis of the latest research shows Kevetrin™ is non-genotoxic, contrary to the majority of currently available chemotherapeutic drugs.  Genotoxic drugs affect nucleic acids and alter their function. These drugs may directly bind with DNA or may indirectly lead to DNA damage by affecting enzymes involved in DNA replication.  A DNA damaging drug results in rapid phosphorylation of H2A.X at Ser 139 by PI3K-like kinases.  Kevetrin™ did not induce phosphorylation of H2A.X protein; whereas, other chemotherapy drugs, such as Adriamycin, did induce the phosphorylation of H2A.X as shown by Western blot assay.  

Research data announced earlier this week showed that Kevetrin™ reactivates p53, a key protein which plays a critical role in mediating cellular stress responses such as that brought about by DNA-damage. It is therefore vital in regulating a vast array of proteins involved in cell cycle progression, DNA repair, and apoptosis.

Dr. Krishna Menon, Chief Scientific Officer at Cellceutix, commented, "This is another major breakthrough for Kevetrin. p53 activation is considered among the critical molecular events for cancer therapy. The fact that Kevetrin™ reactivated p53 and resulted in tumor suppression in animals with drug resistant cancers was a milestone in oncology on its own, but with Kevetrin™ now proven to be non-genotoxic, we believe this has set the compound at the forefront of developmental cancer therapies."  "

Cellceutix is completing formulation production, scheduled for early March 2011, which would produce Kevetrin™ in the dosage form for planned clinical trials. The Company plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in May 2011 with human trials to begin thereafter.

About Cellceutix

Cellceutix Corporation is a preclinical cancer, anti-inflammatory and autism drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, KM-133, for the treatment of psoriasis, and KM-391, for the treatment of autism. More information is available on the Cellceutix web site at www.cellceutix.com.

This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix's actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.

The factors that may cause Cellceutix's actual results to differ from its forward-looking statements include: Cellceutix's current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix's ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix's SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.

Kevetrin, KM133, and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.


'/>"/>
SOURCE Cellceutix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... May 10, 2017 Radiology has become the ... costs have also spiraled to the number one ranking ... radiology than ever before as the most complete and ... patient with lower back pain an MRI may confirm ... for pain, resulting in entirely different treatment protocols.  In ...
(Date:5/9/2017)... May 9, 2017  Semler Scientific, Inc. (OTCQB: ... solutions to improve the clinical effectiveness and efficiency ... the first quarter ended March 31, 2017. ... our customers to identify when preventive care options ... events like heart attacks or strokes occur," said ...
(Date:5/6/2017)... N.Y. , May 5, 2017  Hill-Rom Holdings, ... will add approximately 100,000 square feet to its Welch ... September 2016 its commitment to bring more than 100 ... , where Welch Allyn has maintained a significant presence ... help accommodate these new positions, a large portion of ...
Breaking Medicine Technology:
(Date:5/19/2017)... ... May 19, 2017 , ... The Hill Agencies, a family managed ... throughout the California Central Valley, is announcing a joint charity initiative with the Boys ... a local kid’s camp event. , The Boys and Girls Club of Kern County ...
(Date:5/19/2017)... ... May 19, 2017 , ... The Arnold and Mabel Beckman ... Victor Acosta, Ph.D. - University of New Mexico, Jeremy Baskin, Ph.D. - Cornell ... Washington, Erik Grumstrup, Ph.D. - Montana Stata University, A. Fatih Sarioglu, Ph.D. - ...
(Date:5/19/2017)... ... May 19, 2017 , ... As a groundbreaking surgeon ... the importance of prostate cancer screenings. Early detection of the disease, he says, can ... surgery at Georgia Urology , stands alongside the Georgia Comprehensive Cancer Control’s (GC3) ...
(Date:5/19/2017)... (PRWEB) , ... May 18, 2017 , ... CloSYS products ... for being non-irritating while extremely helpful for mouth and gum health, which is linked ... their professionals and customers learned quickly of the powerful ways in which CloSYS products ...
(Date:5/19/2017)... Santa Clara, CA (PRWEB) , ... May 18, 2017 , ... ... feature that allows sleep labs and physicians to independently dispense CPAP devices and supplies, ... DME orders, and sleep labs can dispense the devices. Device registration for daily usage ...
Breaking Medicine News(10 mins):